Tempus AI (NASDAQ:TEM) Director David Epstein Sells 370 Shares of Company Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $74.29, for a total value of $27,487.30. Following the transaction, the director directly owned 30,474 shares of the company’s stock, valued at approximately $2,263,913.46. The trade was a 1.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Down 2.8%

TEM stock opened at $75.61 on Thursday. The stock has a market capitalization of $13.64 billion, a P/E ratio of -71.33 and a beta of 3.61. The company has a current ratio of 2.61, a quick ratio of 3.16 and a debt-to-equity ratio of 2.70. Tempus AI, Inc. has a 12 month low of $40.77 and a 12 month high of $89.09. The firm has a 50-day moving average price of $71.17 and a 200-day moving average price of $57.20.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. The company had revenue of $411.54 million for the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The firm’s quarterly revenue was up 23.1% compared to the same quarter last year. During the same period last year, the company posted ($0.46) EPS. As a group, equities research analysts anticipate that Tempus AI, Inc. will post -1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. BTIG Research upped their price target on shares of Tempus AI from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. Finally, HC Wainwright increased their price target on Tempus AI from $68.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday. Eleven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus price target of $79.37.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus reported third-quarter revenue of $411.5 million, up 23.1% year over year, and earnings of $0.07 per share—above expectations for a loss. The company also raised its 2026 revenue outlook to about $1.6 billion, citing oncology demand, data partnerships and potential reimbursement-driven pricing gains. Tempus Reports Third Quarter 2026 Results Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
• Positive Sentiment: Several analysts raised their price targets after the results: HC Wainwright to $85, and Baird and Cantor Fitzgerald to $92, with buy/outperform/overweight ratings. Analysts Boost Their Forecasts Following Strong Q3 Results
• Neutral Sentiment: The stock had climbed sharply following earnings, but one report argued it looked fully valued after its recent run. UBS maintained a Hold rating, citing solid oncology execution offset by weaker hereditary testing. Tempus AI Stock Looks Fully Priced Following Its Run UBS Hold Rating
• Negative Sentiment: The CEO and a director disclosed small stock sales, both conducted under pre-arranged Rule 10b5-1 plans. The limited size and planned nature make these sales a relatively weak signal, but they may add to near-term caution. SEC filing
• Negative Sentiment: Investors also face potential integration risks tied to Tempus AI’s proposed Personalis acquisition, which could add execution uncertainty. Personalis Acquisition Integration Risks

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TEM. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the period. Amova Asset Management Americas Inc. boosted its holdings in Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in Tempus AI by 2,965.7% in the third quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock valued at $41,233,000 after acquiring an additional 486,493 shares during the last quarter. Eagle Health Investments LP bought a new stake in Tempus AI in the first quarter valued at approximately $11,588,000. Finally, Aristotle Atlantic Partners LLC bought a new stake in shares of Tempus AI in the 1st quarter valued at $6,179,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.